Susquehanna International Group
ITOS

Susquehanna International Group’s iTeos Therapeutics ITOS Stock Holding History

Susquehanna International Group’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-320,100
Closed -$3.19M – 13150
2025
Q2 		$3.19M Buy
320,100
+177,200
+124% +$1.43M ﹤0.01% 4842
2025
Q1 		$853K Sell
142,900
-929,700
-87% -$6.83M ﹤0.01% 7656
2024
Q4 		$8.24M Buy
1,072,600
+1,050,700
+4,798% +$9.03M ﹤0.01% 2896
2024
Q3 		$224K Sell
21,900
-1,373,100
-98% -$20.9M ﹤0.01% 10240
2024
Q2 		$20.7M Buy
+1,395,000
New +$20M ﹤0.01% 1686
2024
Q1 		– Sell
-691,800
Closed -$7.58M – 12730
2023
Q4 		$7.58M Buy
691,800
+503,500
+267% +$4.99M ﹤0.01% 3033
2023
Q3 		$2.06M Buy
188,300
+135,600
+257% +$1.73M ﹤0.01% 5066
2023
Q2 		$698K Buy
52,700
+24,000
+84% +$342K ﹤0.01% 7528
2023
Q1 		$391K Buy
+28,700
New +$514K ﹤0.01% 9152
2022
Q3 		– Sell
-15,700
Closed -$323K – 13651
2022
Q2 		$323K Buy
15,700
+1,400
+10% +$33.2K ﹤0.01% 9383
2022
Q1 		$460K Buy
+14,300
New +$520K ﹤0.01% 9193

Other funds holding ITOS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Susquehanna International Group's ITOS Position: Q3 2025 in Review

Susquehanna International Group sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 144,080 shares — an estimated $1.44M sold.

Susquehanna International Group first reported a position in ITOS in Q1 2021 and held it in 17 quarters. The position peaked at $3.58M in Q4 2021. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.

  • Susquehanna International Group reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Susquehanna International Group sold 144,080 iTeos Therapeutics shares in Q3 2025, an estimated $1.44M.
  • Susquehanna International Group first reported a position in iTeos Therapeutics in Q1 2021 and held it in 17 quarters.
  • Susquehanna International Group's iTeos Therapeutics position peaked at $3.58M in Q4 2021.
  • 1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.

Based on Susquehanna International Group's 13F filing for Q3 2025, filed 14 Nov 2025.